These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15518433)

  • 1. [Homocysteine as the factor of atherosclerosis risk].
    Jołda-Mydłowska B
    Pol Merkur Lekarski; 2004 May; 16(95):480-3. PubMed ID: 15518433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperhomocysteinemia. A new coronary risk factor].
    Zacarías-Castillo R; Hernández-Rebollar AE; Zajarias-Rabchinskey A; González-Bárcena D
    Gac Med Mex; 2001; 137(4):335-45. PubMed ID: 11519357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease.
    Ndrepepa G; Kastrati A; Braun S; Koch W; Kölling K; Mehilli J; Schömig A
    Clin Chim Acta; 2006 Nov; 373(1-2):70-6. PubMed ID: 16814762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated concentrations of homocysteine in children and adolescents with arterial hypertension accompanying Type 1 diabetes.
    Głowińska B; Urban M; Peczyńska J; Florys B; Szydłowska E
    Med Sci Monit; 2001; 7(6):1242-9. PubMed ID: 11687737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
    Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
    J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Homocysteinemia and coronary artery disease: a case-control study in a Tunisian population].
    Souissi M; Feki M; Mourali S; Enneifer M; Omar S; Sanhaji H; Mechmeche R; Mebazaa A; Kaabachi N
    Arch Mal Coeur Vaiss; 2006 Sep; 99(9):781-5. PubMed ID: 17067095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2.
    de Luis DA; Fernandez N; Arranz ML; Aller R; Izaola O; Romero E
    J Diabetes Complications; 2005; 19(1):42-6. PubMed ID: 15642489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteinemia as an independent risk factor in the Chinese population at a high risk of coronary artery disease.
    Ni M; Zhang XH; Jiang SL; Zhang Y
    Am J Cardiol; 2007 Aug; 100(3):455-8. PubMed ID: 17659928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Consequences of moderate hyperhomocysteinemia in internal medicine].
    Zák A; Zeman M
    Cas Lek Cesk; 2004; 143(6):367-74. PubMed ID: 15309862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of fasting total serum homocysteine levels in liver transplant recipients.
    Akoglu B; Wondra K; Caspary WF; Faust D
    Exp Clin Transplant; 2006 Jun; 4(1):462-6. PubMed ID: 16827644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease.
    Schernthaner GH; Plank C; Minar E; Bieglmayer C; Koppensteiner R; Schernthaner G
    Eur J Clin Invest; 2006 May; 36(5):333-9. PubMed ID: 16634837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
    Perna AF; Castaldo P; Ingrosso D; De Santo NG
    J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hostility and serum homocysteine as cardiovascular risk factors in Korean patients with coronary artery disease.
    Son YJ
    J Clin Nurs; 2007 Apr; 16(4):672-8. PubMed ID: 17402948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
    Von Feldt JM; Scalzi LV; Cucchiara AJ; Morthala S; Kealey C; Flagg SD; Genin A; Van Dyke AL; Nackos E; Chander A; Gehrie E; Cron RQ; Whitehead AS
    Arthritis Rheum; 2006 Jul; 54(7):2220-7. PubMed ID: 16802358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.